SonoTran® Platform

Cancer therapy, re-imagined

Imagine a technology that…

can dramatically enhance drug efficacy and/or reduce drug toxicity for patients.

can be applied to both new and existing anti-cancer drugs and across a wide range of solid tumour cancers without any need for drug reformulation whatsoever.

fits seamlessly into current outpatient care pathway settings and is inherently intuitive, safe and high-throughput for clinicians to use.

provides a comprehensive end-to-end fully scalable solution to healthcare providers.

has the capability to significantly increase the likelihood of clinical trial success for pharma and biotech partners.

SonoTran^® is the only ultrasound-based delivery platform designed to offer all of this.

We have studies running and in planning phase for both approved products and development stage candidates with collaborators – but we’re always interested in maximising the use of SonoTran^® through partnership.

SonoTran^® is ground-breaking. SonoTran^® is totally unique.

Let’s talk

Watch how SonoTran^® works

SonoTran^® Particles

SonoTran^® is designed to hit disease where it hurts

OxSonics’ proprietary SonoTran^® Particles carry a pre-formed stabilised gas bubble that is able to create sustained levels of ‘inertial cavitation’ (bubble expansion and collapse) when exposed to ultrasound at the site of the tumour. This purely mechanical effect is used to actively enhance the transport of unmodified anti-cancer drugs into and throughout tumours. Find out more about the SonoTran^® Platform by watching our animation.

The SonoTran^® Particles are co-administered independently alongside the unmodified anti-cancer drugs. By virtue of their size (400-500 nm), the SonoTran^® Particles have been optimised to circulate in the blood stream, and also to be able to pass into the tumour mass through the leaky endothelium specifically found within solid tumours.

^{For investigational use only, not approved for sale.}

Contact us

Optimal Pharmacokinetics

The in vivo circulation kinetics of SonoTran^® Particles have been designed to be compatible with a broad range, if not all, therapeutic oncology drugs and to provide sufficient time to administer ultrasound to the anatomic region of interest.

Sustained Levels of Cavitation

The in vivo circulation kinetics of SonoTran^® Particles have been designed to be compatible with a broad range, if not all, therapeutic oncology agents and to provide sufficient time to administer ultrasound to the anatomic region of interest.

Range of Administration Routes

SonoTran^® Particles are designed to adopt the same administration route as the oncology drug including intravenous (IV), intra-tumoural (IT) or intraperitoneal (IP).

No Drug Reformulation

The SonoTran^® particles are independently administered alongside the oncology drug, no drug reformulation is required.

Optimal & Consistent Size

The size of the SonoTran^® Particle has been optimised to enable it to pass out of the leaky vasculature typically found in solid tumours so that the Particles can continue to pump the anti-cancer drug further into the tumour tissue.

Clinical Workflow Integration

The SonoTran^® Particles will be delivered to the patient via an infusion bag and administration is designed to fit neatly within current oncology ward out-patient settings.

^{For investigational use only, not approved for sale.}

SonoTran^® System

Combined with SonoTran^® Particles, the SonoTran^® System provides a complete solution optimised for therapeutic use.

The SonoTran^® System is a novel proprietary ultrasound device uniquely designed by OxSonics to image, treat, and monitor target tissue regions in the oncology ward setting. The System uses relatively low diagnostic-level ultrasound pressures focused to a user-selectable target region.

Mobility

For use at the chair-side or bedside in oncology ward / infusion center settings.

Enhanced Treatment Guidance

Potential for co-registration with previously acquired high-resolution patient specific diagnostic CT or MR to real-time ultrasound.

Real Time Treatment Mapping for Optimal Anatomical Coverage

Real-time on-screen mapping and monitoring of treatment using OxSonics’ proprietary patent protected “see-as-you-treat” technology.

Intuitive Useability

Working in collaboration with world-leading oncology radiologists, the enhanced treatment guidance and optimal anatomical guidance features are designed to make the SonoTran^® System intuitive and easy to use by trained junior radiologists or sonographers.

OxSonics plans to provide an installed base of SonoTran^® Systems alongside the provision of training and service and maintenance of Systems. This allows our strategic partners to focus on the commercialisation of the SonoTran^® Particles in combination with their therapeutic agent.

^{For investigational use only, not approved for sale.}

Partnering